CD274 and hepatocellular carcinoma: The IMbrave150 trial, a pivotal phase III study, demonstrated significant advancements in treating advanced hepatocellular carcinoma (HCC) by combining atezolizumab, an anti-PD-L1 antibody, with bevacizumab, an anti-VEGF antibody, showcasing superior overall survival and progression-free survival compared to the standard treatment with sorafenib.